
# Treatment Patterns of Antihypertensive Medications Among Alzheimer's Disease Patients in United States and France



### Wing VK, Buderi R, Vigna C, Rusli E, Galaznik A, Jain R

AcornAl by Medidata, a Dassault Systèmes Company, Boston, MA

PRESENTED AT:



### **BACKGROUND & OBJECTIVES**

#### Background

- Cardiovascular disease (CVD) has been shown to be a risk factor for cognitive decline among patients with Alzheimer's Disease (AD) [1,2]
- Treatments for CVD, including antihypertensives, may reduce cognitive decline among these patients [3-7]
- Due to differences in payment structures between the United States (US) and France, we expect there to be regional variation in compliance to medication

#### Objectives

• The objective of this study was to examine treatment patterns of antihypertensive medication use and clinical characteristics among patients with AD in the US and France

### DATA SOURCES

#### US

- Patient data were extracted from HealthVerity<sup>™</sup> Marketplace longitudinal ambulatory electronic medical record (EMR) dataset between Jan 1, 2014 and Dec 31, 2018
  - HealthVerity<sup>™</sup> has the most complete coverage of United States healthcare, consumer, and purchase data, with access to over 330 million patients and 30 billion transactions [8]. HealthVerity<sup>™</sup> Marketplace is a self-service cloud solution allowing users to build patient and provider cohorts from more than 60 unique data sources.

#### France


- Patient data was extracted from the The Health Improvement Network® (THIN®) France database between July 1, 2016 and June 30, 2019
  - THIN® is an anonymized EMR powered by Cegedim Health Data®-division. THIN® is a large European database, collecting data at the physicians' level.

All data were converted to the Observational Medical Outcomes Partnership (OMOP) Common Data Model, version 5 [9].

Analyses were conducted in Aginity Workbench for Redshift v4.9.3.2873 and R v1.1.456.

## STUDY DESIGN

- Patients with AD (identified by International Classification of Diseases [ICD]-9 code 331.0 or ICD-10 code G30.\*) and  $\geq$  2 years of continuous observation were selected from de-identified electronic medical records in the US between 1/1/2014 and 11/30/2018, and in France between 7/1/2016 to 6/30/2019 (Figure 1)
- · The following treatment patterns of antihypertensive medication use, including thiazide-type diuretics angiotensinconverting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and calcium channel blockers (CCBs), were assessed:
  - Adherent, assessed over 1-year after the patient's earliest antihypertensive medication record (index date) using the novel method described in Biederman et al. (2019) [10]
  - 0 Non-adherent, assessed over 1-year after the patient's earliest antihypertensive medication record (index date)
  - Non-users, defined as having no evidence of antihypertensives use in the first 2 years of observation (index date = observation start date)




#### Figure 1. Selection Criteria and Patient Attrition


\*Out of patients with a prescription, = 2 years of data availability after index date, and non-missing age and sex

- Demographic and clinical characteristics (listed in Table 1) were identified using ICD-9-CM, ICD-10-CM, Anatomical Therapeutic Chemical (ATC), and RxNorm codes for each antihypertensive use category and were assessed during the 1st year post-index date
- · Patient characteristics of antihypertensive medication users were compared to non-users using chi-squared (for categorical variables) and Student's t tests (for continuous variables)

### RESULTS

- In the US population, 50.9% of patients had ≥ 1 record for an antihypertensive; among these patients, 30.1% were adherent while 69.9% were non-adherent (Figure 2)
- In the France population, 12.7% of patients had ≥ 1 record for an antihypertensive; among these patients, 71.9% were adherent while 28.1% were non-adherent (Figure 2)





In the US,

- Adherent patients had a mean age of 76.34 years, a mean Quan's Charlson Comorbidity Index score (QCI) of 1.83, and were using a mean of 2.34 distinct concomitant medications (Table 1)
- Non-adherent patients had a mean age of 77.08 years, a mean QCI of 1.58, and were using a mean of 1.99 distinct concomitant medications
- Non-users of antihypertensives had a mean age of 76.89 years, a mean QCI of 1.05, and were using a mean of 1.45 distinct concomitant medications
- · Across the antihypertensives users and non-users,
  - The top three most common comorbid conditions assessed were depression (adherent: 23.9%; non-adherent: 19.1%; non-users: 19.3%), coronary artery disease (adherent: 18.5%; non-adherent: 15.1%; non-users: 9.6%), and hypothyroidism (adherent: 17.0%; non-adherent: 14.0%; non-users: 14.0%)
  - Approximately one-third of patients were male (adherent: 34.5%; non-adherent: 37.1%; non-users: 36.2%)
- Among antihypertensives users, in both adherent and non-adherent patients, ACE inhibitors were the most commonly
  prescribed antihypertensives, followed by thiazide diuretics, ARBs, and CCBs

In France,

- Adherent patients had a mean age of 76.05 years, a mean QCI of 1.12, and were using a mean of 1.84 distinct concomitant medications (Table 1)
- Non-adherent patients had a mean age of 75.89 years, a mean QCI of 1.03, and were using a mean of 1.54 distinct concomitant medications
- Non-users of antihypertensives had a mean age of 63.76 years, a mean QCI of 0.64, and were using a mean of 0.86 distinct concomitant medications
- · Across the antihypertensives users and non-users,
  - The top three most common comorbid conditions assessed were mild cognitive impairment (100% of all patients), depression (adherent: 19.7%; non-adherent: 11.9%; non-users: 10.5%), and hypothyroidism (adherent: 9.7%; non-adherent: 8.9%; non-users: 5.9%)

#### ispor (iPosterSessions - an aMuze! Interactive system)

- Approximately 40% of patients were male (adherent: 42.7%; non-adherent: 43.9%; non-users: 35.5%)
- Among antihypertensives users, in both adherent and non-adherent patients, ARBs were the most commonly prescribed antihypertensives, followed by ACE inhibitors, CCBs, and thiazide diuretics

#### Table 1. Demographic and Clinical Characteristics By Antihypertensive Use and Country

	us						France					
	Adherent		Non-Adherent		Non-Users		Adherent		Non-Adherent		Non-Users	
	N=	2,179	N=	5,068	N=	7,939	N=	1,117	N=	437	N=	7,428
Patient Characteristic	N/Mean	%/SD	N/Mean	%/SD	N/Mean	%/SD	N/Mean	%/SD	N/Mean	%/SD	N/Mean	%/SD
Demographics									2			
Age (mean, SD)	76.34 <sup>4</sup>	7.96	77.08	8.04	76.89	8.89	76.05 <sup>3</sup>	10.64	75.89 <sup>3</sup>	11.33	63.76	22.23
Male (n, %)	752	34.5%	1,878	37.1%	2,877	36.2%	477 <sup>3</sup>	42.7%	192 <sup>3</sup>	43.9%	2,635	35.5%
Clinical Characteristic												
Quan's Charlson Comorbidity	2		2				2		2			
Index score <sup>1</sup> (mean, SD) Number of distinct concomitant	1.83 <sup>3</sup>	1.92	1.58 <sup>3</sup>	1.86	1.05	1.61	1.12 <sup>3</sup>	1.07	1.03 <sup>3</sup>	1.02	0.64	0.78
medications <sup>2</sup> (mean, SD)	2.34 <sup>3</sup>	1.69	1.99 <sup>3</sup>	1.58	1.45	1.54	1.84 <sup>3</sup>	1.35	1.54 <sup>3</sup>	1.33	0.86	1.14
Atrial fibrillation (n, %)	349 <sup>3</sup>	16.0%	546*	10.8%	665	8.4%	3	0.3%	0	0.0%	8	0.1%
Bipolar disorder (n, %)	19	0.9%	43	0.8%	93	1.2%	1	0.1%	1	0.2%	22	0.3%
Coronary artery disease (n, %)	403 <sup>3</sup>	18.5%	764 <sup>3</sup>	15.1%	762	9.6%	79 <sup>3</sup>	7.1%	30 <sup>3</sup>	6.9%	116	1.6%
Depression (n, %)	520 <sup>3</sup>	23.9%	966	19.1%	1529	19.3%	220 <sup>3</sup>	19.7%	52	11.9%	779	10.5%
Epilepsy (n, %)	105	4.8%	177 <sup>5</sup>	3.5%	350	4.4%	12	1.1%	6	1.4%	91	1.2%
Glaucoma (n, %)	45 <sup>4</sup>	2.1%	87 <sup>5</sup>	1.7%	101	1.3%	7 <sup>5</sup>	0.6%	4 <sup>4</sup>	0.9%	13	0.2%
Hearing loss (n, %)	106	4.9%	252	5.0%	340	4.3%	14	1.3%	4	0.9%	51	0.7%
Hyperthyroidism (n, %)	17 <sup>5</sup>	0.8%	27	0.5%	32	0.4%	6	0.5%	4	0.9%	55	0.7%
Hypothyroidism (n, %)	370 <sup>4</sup>	17.0%	707	14.0%	1113	14.0%	108 <sup>3</sup>	9.7%	39 <sup>5</sup>	8.9%	435	5.9%
Mild cognitive impairment (n, %)	95	4.4%	223	4.4%	317	4.0%	1,117	100.0%	437	100.0%	7,428	100.0%
Osteoporosis (n, %)	154 <sup>5</sup>	7.1%	326 <sup>3</sup>	6.4%	690	8.7%	23 <sup>3</sup>	2.1%	6	1.4%	43	0.6%
Parkinson's disease (n, %)	41	1.9%	102 <sup>5</sup>	2.0%	205	2.6%	17	1.5%	8	1.8%	112	1.5%
Pneumonia (n, %)	56 <sup>4</sup>	2.6%	101	2.0%	133	1.7%	19 <sup>5</sup>	1.7%	4	0.9%	65	0.9%
Schizophrenia (n, %)	8	0.4%	22 <sup>5</sup>	0.4%	61	0.8%	0	0.0%	0	0.0%	3	0.0%
Stroke/Transient ischemic attack												
(n, %)	156 <sup>3</sup>	7.2%	311 <sup>3</sup>	6.1%	292	3.7%	57 <sup>3</sup>	5.1%	19 <sup>3</sup>	4.3%	110	1.5%
Antihypertensive Medication Use				_						_		
Thiazide diuretics	965	44.3%	1694	33.4%			101	9.0%	26	6.0%		
ARBs	792	36.4%	1533	30.3%			525	47.0%	191	43.7%		
CCBs	363	16.7%	545	10.8%			187	16.7%	67	15.3%		
ACE Inhibitors	1,292	59.3%	2724	53.8%			471	42.2%	177	40.5%		

<sup>1</sup>Quan H, Sundararajan V, Halfon P, et al. Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data: Medical Care. 2005;43(11):1130-1139 <sup>2</sup>Included treatment agents from the following medication classes: Alzheimer's medications, antiplatelets, statins, antipsychotics, anxiolytics, and antidepressants

<sup>3</sup>p<0.001 when compared to no antihypertensive use

<sup>4</sup>p<0.01 when compared to no antihypertensive use

 $^{5}\mathrm{p}{<}0.05$  when compared to no antihypertensive use

#### Comparing the US and France,

- · Antihypertensives non-users were over 10 years younger in France compared to in the US
- QCI scores and number of distinct concomitant medications were lower across the antihypertensives users and non-users in France compared to in the US
- The prevalence of comorbidities were lower in France in all conditions (except mild cognitive impairment) and across the antihypertensives users and non-users compared to in the US
  - Notably, atrial fibrillation was observed in 8.4% to 16.0% of patients in the US while between 0.1% and 0.3% were observed in France
  - Mild cognitive impairment was observed in 100% of all patients in France, while it was observed in 4.0% to 4.4% of patients in the US
- Choice of antihypertensives prescribed by providers differed between the two countries; thiazide diuretics were the least prescribed in France (9.0% and 6.0%) while being the second most commonly prescribed in the US (44.3% and 33.4%), and ACE inhibitors were the most commonly prescribed in the US (59.3% and 53.8%) while ARBs were the most prescribed in France (47.0% and 43.7%)

### LIMITATIONS

- Studies using EMR data sources assume patients filled and took their medications as prescribed. Using reimbursement claims-based data sources may provide more accurate measurement of patient adherence to antihypertensive medications
- Patients assessed from France were limited to those with an activity within a pre-specified 3-year period, yielding small sample sizes of antihypertensive users from this population and may not be representative of entire France population of antihypertensive users
- This study is subject to limitations in accuracy and consistency of medical coding as is common for studies using EMR

## **CONCLUSIONS & DISCUSSION**

- In the US population, patients prescribed antihypertensives were more likely to be non-adherent, while the opposite was true in the France population, possibly driven by differences in medical practice and access to care
- Drivers of the lower QCI, number of distinct concomitant medications use, and prevalence of comorbid conditions observed in France may include a generally healthier lifestyle and population in France [11], differences in medical coding and diagnosis practices, and the absence of specialized hospitals in the THIN network; these may also explain the large differences observed in the prevalence of atrial fibrillation and mild cognitive impairment between the two countries
- Differences were observed in the choice of antihypertensive medications prescribed to patients, suggesting clinical guidelines for antihypertensive treatment may differ between the two countries
- Further research is needed to identify modifiable characteristics associated with non-adherence of antihypertensives in patients with AD in these countries

## AUTHOR INFORMATION

Vicki K Wing, MS - vwing@mdsol.com

Robbie Buderi, BA - rbuderi@mdsol.com

Chelsea Vigna, MPH - cvigna@mdsol.com

Emelly Rusli, MPH - erusli@mdsol.com

Aaron Galaznik, MD, MBA - agalaznik@mdsol.com

Rahul Jain, PhD - rajain@mdsol.com

### REFERENCES

1. de Bruijn RF, Ikram MA. Cardiovascular risk factors and future risk of Alzheimer's disease. BMC Med. 2014;12. doi:10.1186/s12916-014-0130-5

2. Wanleenuwat P, Iwanowski P, Kozubski W. Alzheimer's dementia: pathogenesis and impact of cardiovascular risk factors on cognitive decline. Postgrad Med. 2019;131(7):415-422. doi:10.1080/00325481.2019.1657776

3. Hajjar I, Brown L, Mack WJ, Chui H. Impact of angiotensin receptor blockers on Alzheimer's disease neuropathology in a large brain autopsy series. Arch Neurol. 2012;69(12):1632-1638. doi:10.1001/archneurol.2012.1010

4. Wang J, Zhao Z, Lin E, et al. Unintended Effects of Cardiovascular Drugs on the Pathogenesis of Alzheimer's Disease. PLoS ONE. 2013;8(6). doi:10.1371/journal.pone.0065232

5. Rosenberg PB, Mielke MM, Tschanz J, et al. Effects of Cardiovascular Medications on Rate of Functional Decline in Alzheimer Disease. Am J Geriatr Psychiatry. 2008;16(11):883-892. doi:10.1097/JGP.0b013e318181276a

6. Deschaintre Y, Richard F, Leys D, Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology. 2009;73(9):674-680. doi:10.1212/WNL.0b013e3181b59bf3

7. Duron E, Rigaud A-S, Dubail D, et al. Effects of Antihypertensive Therapy on Cognitive Decline in Alzheimer's Disease. Am J Hypertens. 2009;22(9):1020-1024. doi:10.1038/ajh.2009.119

8. HealthVerity Overview. Accessed October 27, 2020. https://healthverity.com/wp-content/uploads/HealthVerity-Overview.pdf

9. Observational Health Data Sciences and Informatics. OMOP Common Data Model. Accessed April 29, 2020. https://www.ohdsi.org/data-standardization/the-common-data-model/

10. Biederman J, Fried R, DiSalvo M, et al. Evidence of Low Adherence to Stimulant Medication Among Children and Youths With ADHD: An Electronic Health Records Study. Psychiatr Serv Wash DC. 2019;70(10):874-880. doi:10.1176/appi.ps.201800515

11. Richard JL. [Coronary risk factors. The French paradox]. Arch Mal Coeur Vaiss. 1987;80 Spec No:17-21.